3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 12 areas
0
News (30d)
Quiet
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a company with 3 orphan drug designations across 5 rare diseases. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| biliary tract cancer | trastuzumab-rezetecan | Des.TrialAppr. |
| gastric cancer | trastuzumab-rezetecan | Des.TrialAppr. |
| malignant carotid body paraganglioma | Hetrombopag olamine, Rafutrombopag | Des.TrialAppr. |
| post-treatment Lyme disease syndrome | Hetrombopag olamine, Rafutrombopag | Des.TrialAppr. |
| treatment-refractory schizophrenia | Hetrombopag olamine, Rafutrombopag | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
87
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
87
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
1
affecting portfolio